Literature DB >> 1976073

Structural determination of the conjugated metabolites of ritodrine.

W T Brashear1, B R Kuhnert, R Wei.   

Abstract

Ritodrine is a beta-2 adrenergic agonist which is used clinically for the management of preterm labor. Since ritodrine is resistant to the action of monoamine oxidase and catecholamine-O-methyltransferase, conjugation is a major route of metabolism. Glucuronide and sulfate conjugates of ritodrine are found in maternal urine. However, the structure of these metabolites has not been determined. The purpose of this study was to determine the structure of these conjugates. Urine from patients on ritodrine therapy was purified by QAE Sephadex ion exchange chromatography. The partially purified conjugates were derivatized and analyzed by GC/MS. The data did not indicate an exclusive site of conjugation. Analysis of both the glucuronide and sulfate conjugates indicates that either of the two phenolic hydroxyl groups may be involved in the formation of conjugated metabolites. However, conjugation of the [2-(p-hydroxyphenyl)-2-hydroxy-1-methylethyl]amine phenolic hydroxyl is more prevalent for both conjugates. This phenolic hydroxyl group is unique since it is located on the portion of the ritodrine molecule which more closely resembles the structure of endogenous catecholamines.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1976073

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  2 in total

1.  Metabolism of 4-[1-(2-fluoro-4-biphenylyl)ethyl]-2-methylaminothiazole (SM-8849) in rats.

Authors:  M Yabuki; J Shimakura; M Ito; H Kanamaru; K Iba; I Nakatsuka
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Jan-Mar       Impact factor: 2.441

2.  Inhibitory effects of various beverages on ritodrine sulfation by recombinant human sulfotransferase isoforms SULT1A1 and SULT1A3.

Authors:  Haruka Nishimuta; Masayuki Tsujimoto; Kenichiro Ogura; Akira Hiratsuka; Hisakazu Ohtani; Yasufumi Sawada
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.